Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. The vaginal pessary formulation is used for the topical treatment of vulvovaginal candidiasis. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infection). ## Adult Dosing * **One (1) miconazole 100 mg vaginal pessary inserted vaginally at bedtime for 7 consecutive nights.** ## Pediatric Dosing * Dosing in pediatric patients has not been established. Use in pediatric patients is generally not recommended unless specifically directed by a healthcare provider. ## Dose Adjustments * No dose adjustments are typically required based on renal or hepatic impairment for topical vaginal administration. ## Contraindications * Hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects * Common: Vulvar/vaginal burning or itching, vaginal discharge, pelvic cramps. * Less Common: Rash, hives. ## Key Drug Interactions * **Warfarin:** Miconazole (especially oral or higher systemic exposures) can inhibit CYP2C9, potentially increasing the international normalized ratio (INR) and risk of bleeding with warfarin. While topical vaginal absorption is low, caution is advised, and INR monitoring may be warranted if systemic symptoms occur or if used concurrently with oral miconazole. * **CYP3A4 Substrates:** Miconazole is a moderate inhibitor of CYP3A4. Concurrent use with other medications metabolized by CYP3A4 (e.g., certain statins, benzodiazepines, calcium channel blockers) could theoretically increase systemic concentrations of these drugs. However, systemic absorption from vaginal pessaries is minimal, making significant interactions unlikely. ## Monitoring * Monitor for signs and symptoms of vulvovaginal candidiasis. * Monitor for and manage any adverse effects. * If using concurrently with warfarin, monitor INR closely. ## Clinical Pearls * Ensure the pessary is fully inserted into the vagina. * Complete the full course of treatment, even if symptoms improve earlier. * Avoid intercourse during treatment. * If symptoms persist or worsen after treatment, re-evaluate the diagnosis. * Pregnancy: While systemic absorption is low, consult with a healthcare provider regarding use during pregnancy, particularly in the first trimester. *** *This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on specific patient factors and local protocols.*